IP Library Granted Patent US 9,517,271
Granted Patent B2
US 9,517,271 · App. 14/957,148 · Granted Dec 13, 2016

Oral drug delivery system

Inventors: Su Il Yum (Los Altos, CA); Grant Schoenhard (San Carlos, CA); Arthur J. Tipton (Birmingham, AL); John W. Gibson (Springville, AL); John C. Middleton (Fort Collins, CO); Roger Fu (Saratoga, CA); Michael S. Zamloot (Austin, TX)
Assignee: DURECT CORPORATION
A61K47/38A61K9/48A61K9/4858A61K9/4866A61K31/4458A61K31/485A61K47/14A61K47/26Y10S514/96
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,517,271
App. No.
14/957,148
Granted
Dec 13, 2016
Kind
B2
Abstract

Dosage forms and drug delivery devices suitable for administration of pharmaceutical compounds and compositions, including the oral drug administration of compounds.

Claims (33)

1. A composition comprising:

a drug;

sucrose acetate isobutyrate (SAIB);

a cellulose acetate butyrate (CAB) having at least one feature selected from a butyryl content ranging from about 17% to about 38%, an acetyl content ranging from about 13% to about 30%, and a hydroxyl content ranging from about 0.8% to about 1.7%; and

a solvent.

2. The composition of claim 1 , wherein the drug is present in an amount ranging from about 2 mg to about 250 mg.

3. The composition of claim 1 , wherein the composition comprises from about 20 weight percent to about 90 weight percent of the SAIB.

4. The composition of claim 1 , wherein the CAB has a butyryl content ranging from about 17% to about 38%.

5. The composition of claim 1 , wherein the CAB has an acetyl content ranging from about 13% to about 30%.

6. The composition of claim 1 , wherein the CAB has a butyryl content ranging from about 17% to about 38% and an acetyl content ranging from about 13% to about 30%.

7. The composition of claim 1 , wherein the composition comprises from about 1 weight percent to about 8.6 weight percent of the CAB.

8. The composition of claim 1 , wherein the composition comprises from about 20 weight percent to about 50 weight percent of the solvent.

9. The composition of claim 1 , wherein the solvent comprises propylene carbonate, N-methylpyrrolidone (NMP), glycofurol, alpha-tocopherol, diethyl phthalate, or polyethylene glycol 400 (PEG 400).

10. The composition of claim 1 , wherein the solvent comprises triacetin or ethyl lactate.

11. The composition of claim 1 , wherein the solvent comprises triacetin.

12. The composition of claim 1 , further comprising a member selected from caprylic/capric triglyceride, isopropyl myristate (IPM), ethyl oleate, dimethyl phthalate, and benzyl benzoate.

13. The composition of claim 1 , further comprising isopropyl myristate (IPM).

14. The composition of claim 13 , wherein the composition comprises from about 1 weight percent to about 75 weight percent of the IPM.

15. The composition of claim 13 , wherein the composition comprises:

from about 20 weight percent to about 90 weight percent of the SAM;

from about 1 weight percent to about 8.6 weight percent of the CAB;

from about 1 weight percent to about 75 weight percent of the IPM; and

from about 20 weight percent to about 50 weight percent of the solvent.

16. The composition of claim 15 , wherein the composition comprises from 3 weight percent to 7.8 weight percent of the CAB.

17. The composition of claim 16 , wherein the composition comprises from 1 weight percent to 10 weight percent of the IPM.

18. The composition of claim 16 , wherein the composition comprises:

from about 30 weight percent to about 70 weight percent of the SAM; and

from about 25 weight percent to about 48 weight percent of the solvent.

19. The composition of claim 1 , wherein the composition is contained in a capsule.

20. The composition of claim 19 , wherein the capsule comprises gelatin or hydroxyl propylmethyl cellulose.

21. The composition of claim 20 , wherein the capsule comprises a hard capsule comprising gelatin or hydroxyl propylmethyl cellulose.

22. A method of providing pain relief to a subject in need thereof, the method comprising:

orally administering to the subject an effective amount of the composition of claim 1 , wherein the drug comprises an opioid.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 28, 2016
From: FU, ROGER; ZAMLOOT, MICHAEL S.
To: PAIN THERAPEUTICS, INC.
Reel/Frame 038116/0621 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 28, 2016
From: PAIN THERAPEUTICS, INC.
To: DURECT CORPORATION
Reel/Frame 038116/0703 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 28, 2016
From: YUM, SU IL; SCHOENHARD, GRANT; TIPTON, ARTHUR J.; GIBSON, JOHN W.; MIDDLETON, JOHN C.
To: DURECT CORPORATION
Reel/Frame 038116/0710 →
Continuity (7)
Continuation 14574024 · Dec 17, 2014
Continuation 13786118 · Mar 5, 2013
Continuation 13366168 · Feb 3, 2012
Continuation 10737144 · Dec 15, 2003
Provisional Application 60517464 · Nov 4, 2003
Provisional Application 60433116 · Dec 13, 2002
Related Publication 20160193345A1 · Jul 7, 2016